Immusoft Receives Rare Pediatric Disease Designation
17.10.2018
Immusoft Receives Rare Pediatric Disease Designation for Treatment of MPS I
News
Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline
14.09.2018
Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline
Immusoft Receives $3.5 Million Grant to Expand upon Its Cell Therapy Platform
05.09.2018
Federal grant will be used to help company advance B cell technology
Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium
23.08.2018
Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile.
Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study
02.08.2018
SHINE-1 Results Suggest EB-001A May Improve Appearance of Scars.